CoChat
Sign Up
Cited by 187Dementia and Cognitive Impairment ResearchCholinesterase and Neurodegenerative DiseasesAlzheimer's disease research and treatments

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model

Molchan, Susan E., Martinez, Rick A., Hill, James L., Weingartner, Herbert J., Thompson, Karen, Vitiello, Benedetto, Sunderland, Trey·1992·Brain Research Reviews
DOI 10.1016/0165-0173(92)90017-g
Open this paper in CoChat — free account

Abstract

18 older normal volunteers (mean age = 66.5 +/- 7.9 years) and 46 younger volunteers (mean age = 27.0 +/- 6.1 years) were administered the anticholinergic drug scopolamine (0.5 mg i.v.) followed by a battery of cognitive tests evaluating attention, learning and memory. The older subjects were significantly more impaired than the younger by scopolamine on some tests of learning and memory. This increased sensitivity of the older group to scopolamine is consistent with studies in animals and humans showing decreased cholinergic system function with age. The findings also indicate that age is an important variable to consider in using the scopolamine model of memory impairment. The cognitive impairment caused by scopolamine in younger subjects in this and prior studies is similar to some, but not all aspects of the impairment which occurs in normal aging. Scopolamine also caused impairments on digit span and word fluency tasks, which are not consistent with normal aging changes. In the older group of subjects, scopolamine produced aspects of the cognitive impairment which occurs in AD on tests of episodic memory and learning, vigilance-attention, category retrieval, digit span, and number of intrusions. Other areas of cognition that are of relevance to aging and AD such as psychomotor speed, praxis, concept formation and remote memory were not evaluated in this study. Some of these are being evaluated in ongoing studies, along with additional and more specific tests of retrieval…

Overview

Integrity signals

Registry

Crossref · 10.1016/0165-0173(92)90017-g

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A well-known risk with anticholinergic medications is acute impairment in specific aspects of cognition (e.g., working memory, attention, psychomotor speed), demonstrated in single dose experimental studies and cohort studies.

    “A well-known risk with anticholinergic medications is acute impairment in specific aspects of cognition (e.g., working memory, attention, psychomotor speed) which has been demonstrated in single dose experimental studies 9-12 and cohort studies.13”

    From Cumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study (2015) · cites this paper as [10]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 101

  1. Baddeley, 1992, Working memory, Science, 255, 556, 10.1126/science.1736359 · DOI · Paper page
  2. Bartus, 1978, Evidence for a direct cholinergic involvement in the scopolamine-induced amnesia in monkeys: effects of concurrent administration of physostigmine and methylphenidate with scopolamine, Pharmacol. Biochem. Behav., 9, 833, 10.1016/0091-3057(78)90364-7 · DOI
  3. Bartus, 1982, The cholinergic hypothesis of geriatric memory dysfunction, Science, 217, 408, 10.1126/science.7046051 · DOI · Paper page
  4. Battig, 1969, Category norms for verbal items in 56 categories, J. Exp. Psychol. Monogr., 80, 1, 10.1037/h0027577 · DOI
  5. Beatty, 1986, Patterns of memory failure after scopolamine treatment: implications for cholinergic hypotheses of dementia, Behav. Neural Biol., 45, 196, 10.1016/S0163-1047(86)90772-7 · DOI
  6. Borkowski, 1967, Word fluency and brain damage, Neuropsychologia, 5, 135, 10.1016/0028-3932(67)90015-2 · DOI
  7. Branconnier, 1982, Amitriptyline selectively disrupts verbal recall from secondary memory of the normal aged, Neurobiol. Aging, 3, 55, 10.1016/0197-4580(82)90061-6 · DOI
  8. Brandeis, 1990, Reversal of age-related cognitive impairments by an M1 cholinergic agonist, AF102B, Pharmacol. Biochem. Behav., 36, 89, 10.1016/0091-3057(90)90131-Z · DOI
  9. Buschke, 1973, Selective reminding for analysis of memory and learning, J. Verb. Learn. Verb. Behav., 12, 543, 10.1016/S0022-5371(73)80034-9 · DOI
  10. Buschke, 1986, Genuine memory deficits in age-associated memory impairment, Dev. Neuropsychol., 2, 287, 10.1080/87565648609540350 · DOI
  11. Butters, 1987, Episodic and semantic memory: a comparison of amnesic and demented patients, J. Clin. Exp. Neuropsychol., 9, 479, 10.1080/01688638708410764 · DOI
  12. Caine, 1981, Qualitative analysis of scopolamine-induced amnesia, Psychopharmacology, 74, 74, 10.1007/BF00431761 · DOI
  13. Callaway, 1985, Effects of oral scopolamine on human stimulus evaluation, Psychopharmacology, 85, 133, 10.1007/BF00428401 · DOI
  14. Cheal, 1981, Scopolamine disrupts maintenance of attention rather than memory processes, Behav. Neural Biol., 33, 163, 10.1016/S0163-1047(81)91612-5 · DOI
  15. Costa, 1983, The transsynaptic regulation of the septal-hippocampal cholinergic neurons, Life Sci., 32, 165, 10.1016/0024-3205(83)90028-0 · DOI
  16. Coyle, 1983, Alzheimer's disease: a disorder of cortical cholinergic innervation, Science, 219, 1184, 10.1126/science.6338589 · DOI
  17. Craik, 1990, Changes in memory with normal aging: a functional view, Adv. Neurol., 51, 201
  18. Crow, 1973, An analysis of the learning deficit following hyoscine administration to man, Br. J. Pharmacol., 49, 322, 10.1111/j.1476-5381.1973.tb08379.x · DOI
  19. Curran, 1991, Models of memory dysfunction? A comparison of the effects of scopolamine and lorazepam on memory, psychomotor performance and mood, Psychopharmacology, 103, 83, 10.1007/BF02244079 · DOI
  20. Danion, 1990, Effects of scopolamine, trimipramine and diazepam on explicit memory and repetition priming in healthy volunteers, Psychopharmacology, 102, 422, 10.1007/BF02244116 · DOI
  21. Davies, 1976, Selective loss of central cholinergic neurons in Alzheimer's disease, Lancet, ii, 1403, 10.1016/S0140-6736(76)91936-X · DOI · Paper page
  22. Davies, 1971, Confusional episodes and antidepressant medication, Am. J. Psychiatr., 128, 95, 10.1176/ajp.128.1.95 · DOI
  23. Davis, 1979, Enhancement of memory by physostigmine, N. Eng. J. Med., 301, 946, 10.1056/NEJM197910253011721 · DOI
  24. Decker, 1987, The effects of aging on hippocampal and cortical projections of the forebrain cholinergic system, Brain Res. Rev., 12, 423, 10.1016/0165-0173(87)90007-5 · DOI
  25. Decker, 1988, Effects of training on a spatial memory task on high affinity choline uptake in hippocampus and cortex in young adult and aged rats, J. Neurosci., 8, 90, 10.1523/JNEUROSCI.08-01-00090.1988 · DOI
  26. Drachman, 1977, Memory and cognitive function in man: does the cholinergic system have a specific role?, Neurology, 27, 783, 10.1212/WNL.27.8.783 · DOI
  27. Drachman, 1974, Human memory and the cholinergic system, Arch. Neurol., 30, 113, 10.1001/archneur.1974.00490320001001 · DOI
  28. Drachman, 1980, Arch. Neurol., 37, 674, 10.1001/archneur.1980.00500590098022 · DOI
  29. Dunne, 1990, Scopolamine and sustained retrieval from semantic memory, J. Psychopharmacol., 4, 13, 10.1177/026988119000400103 · DOI
  30. Dunne, 1985, The effects of scopolamine upon verbal memory: evidence for an attentional hypothesis, Acta Psychol., 58, 205, 10.1016/0001-6918(85)90020-4 · DOI
  31. Dunne, 1986, Scopolamine and the control of attention in humans, Psychopharmacology, 89, 94, 10.1007/BF00175197 · DOI
  32. Eslinger, 1985, Neuropsychologic detection of abnormal mental decline in older persons, JAMA, 253, 670, 10.1001/jama.253.5.670 · DOI
  33. Flicker, 1986, Cognitive decline in advanced age: future directions for the psychometric differentiation of normal and pathological age changes in cognitive function, Dev. Neuropsychol., 2, 309, 10.1080/87565648609540351 · DOI
  34. Flicker, 1992, Hypersensitivity to scopolamine in the elderly, Psychopharmacology, 107, 437, 10.1007/BF02245172 · DOI · Paper page
  35. Flicker, 1990, Scopolamine effects on memory, language, visuospatial praxis and psychomotor speed, Psychopharmacology, 100, 243, 10.1007/BF02244414 · DOI · Paper page
  36. Frith, 1989, The effects of scopolamine and clonidine upon the performance and learning of a motor skill, Psychopharmacology, 98, 120, 10.1007/BF00442017 · DOI
  37. Fuld, 1982, Intrusions as a sign of Alzheimer dementia: chemical and pathological verification, Ann. Neurol., 11, 155, 10.1002/ana.410110208 · DOI
  38. Galey, 1989, In vivo modulation of septo-hippocampal cholinergic activity in mice: relationships with spatial reference and working memory performance, Behav. Brain Res., 32, 163, 10.1016/S0166-4328(89)80082-8 · DOI
  39. Ghoneim, 1975, Effects of diazepam and scopolamine on storage, retrieval and organizational process in memory, Psychopharmacologia, 44, 257, 10.1007/BF00428903 · DOI
  40. Gibson, 1981, Brain acetyulcholine declines with senescence, Science, 213, 674, 10.1126/science.7256270 · DOI
  41. Grafman, 1990, Implicit learning in patients with Alzheimer's disease, Pharmacopsychiatry, 23, 94, 10.1055/s-2007-1014490 · DOI
  42. Greenblatt, 1982, Drug disposition in old age, N. Eng. J. Med., 306, 1081, 10.1056/NEJM198205063061804 · DOI
  43. Grober, 1989, Does scopolamine directly impair memory?, J. Cogn. Neurosci., 1, 327, 10.1162/jocn.1989.1.4.327 · DOI
  44. Hasher, 1984, Automatic processing of fundamental information: the case of frequency of occurrence, Am. Psychol., 39, 1372, 10.1037/0003-066X.39.12.1372 · DOI
  45. Ingram, 1981, Age and neurochemical correlates of radial maze performance in rats, Neurobiol. Aging, 2, 41, 10.1016/0197-4580(81)90058-0 · DOI
  46. Katzman, 1986, Medical progress: Alzheimer's disease, N. Engl. J. Med., 314, 964, 10.1056/NEJM198604103141506 · DOI · Paper page
  47. Ketchum, 1973, Atropine, scopolamine and Ditran: comparative pharmacology and antagonists in man, Psychopharmacologia, 28, 121, 10.1007/BF00421398 · DOI
  48. Knopman, 1991, Unaware learning versus preserved learning in pharmacologic amnesia: similarities and differences, J. Exp. Psychol., 17, 1017
  49. Knopman, 1987, Implicit learning in patients with probable Alzheimer's disease, Neurology, 37, 784, 10.1212/WNL.37.5.784 · DOI
  50. Kopelman, 1986, The cholinergic neurotransmitter system in human memory and dementia: a review, Q. J. Exp. Psychol., 38A, 535, 10.1080/14640748608401614 · DOI
  51. Kopelman, 1988, Cholinergic ‘blockade’ as a model for cholinergic depletion, Brain, 111, 1079, 10.1093/brain/111.5.1079 · DOI
  52. Lebrun, 1990, A comparison of the working memory performances of young and aged mice combined with parallel measures of testing and drug-induced activations of septo-hippocampal and non-cortical cholinergic neurones, Neurobiol. Aging, 11, 515, 10.1016/0197-4580(90)90112-D · DOI
  53. Liljequist, 1979, Effect of physostigmine and scopolamine on the memory functions of chess players, Med. Biol., 57, 402
  54. Lines, 1991, The effects of scopolamine on retrieval from semantic memory, J. Psychopharmacol., 5, 234, 10.1177/026988119100500309 · DOI
  55. Lippa, 1985, Conformational changes in muscarinic receptors may produce diminished cholinergic neuro-transmission and memory deficits in aged rats, Neurobiol. Aging, 6, 317, 10.1016/0197-4580(85)90010-7 · DOI
  56. Mann, 1984, Alzheimer's presenile dementia, senile dementia of Alzheimer type and Down's syndrome in middle age form an age related continuum of pathological changes, Neuropathol. Appl. Neurobiol., 10, 185, 10.1111/j.1365-2990.1984.tb00351.x · DOI
  57. Marcyniuk, 1989, The topography of nerve cell loss from the locus coeruleus in elderly persons, Neurobiol Aging, 10, 5, 10.1016/S0197-4580(89)80004-1 · DOI
  58. Mash, 1985, Loss of M2 muscarinic receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation, Science, 228, 1115, 10.1126/science.3992249 · DOI
  59. Mewaldt, 1979, The effects of interactions of scopolamine, physostigmine and methamphetamine on human memory, Pharmacol Biochem. Behav., 10, 205, 10.1016/0091-3057(79)90088-1 · DOI
  60. Mohs, 1981, Partial reversal of anticholinergic amnesia by choline chloride, Life Sci., 29, 1317, 10.1016/0024-3205(81)90674-3 · DOI
  61. Molchan, 1990, TRH attenuates scopolamine-induced memory impairment in humans, Psychopharmacology, 100, 84, 10.1007/BF02245795 · DOI
  62. Morris, 1986, The memory deficits in Alzheimer-type dementia: a review, Q. J. Exp. Psychol., 38A, 575, 10.1080/14640748608401615 · DOI
  63. Newhouse, 1988, The effects of acute scopolamine in geriatric depression, Arch. Gen. Psychiatry, 45, 906, 10.1001/archpsyc.1988.01800340028004 · DOI
  64. Nissen, 1987, Neurochemical dissociation of memory systems, Neurology, 37, 789, 10.1212/WNL.37.5.789 · DOI
  65. Nordberg, 1981, Cholinergic receptors in human hippocampus-Regional distribution and variance with age, Life Sci., 29, 1937, 10.1016/0024-3205(81)90601-9 · DOI
  66. O'Connor, 1980, Slow potential correlates of attention dysfunction in senile dementia, Biol. Psychol., 11, 193, 10.1016/0301-0511(80)90055-1 · DOI
  67. Ober, 1985, Processes of verbal memory failure in Alzheimer-type dementia, Brain Cognit., 4, 90, 10.1016/0278-2626(85)90056-9 · DOI
  68. Pedigo, 1988, Pharmacological adaptations and muscarinic receptor plasticity in hypothalamus of senescent rats treated chronically with cholinergic drugs, Psychopharmacology, 95, 497, 10.1007/BF00172962 · DOI
  69. Perry, 1978, Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia, Br. Med. J., 2, 1457, 10.1136/bmj.2.6150.1457 · DOI
  70. Preston, 1988, The scopolamine model of dementia: determination of central cholinomimetic effects of physostigmine on cognition and biochemical markers in man, J. Psychopharmacol., 2, 67, 10.1177/026988118800200202 · DOI
  71. Ray, 1992, Central anticholinergic hypersensitivity in aging, J. Geriatric Psychiatr. Neurol., 5, 72, 10.1177/002383099200500203 · DOI · Paper page
  72. Richardson, 1984, The effects of intravenous diazepam and hyoscine upon recognition memory, Behav. Brain Res., 14, 193, 10.1016/0166-4328(84)90188-8 · DOI
  73. Rinne, 1987, Muscarinic and dopaminergic receptors in the aging human brain, Brain Res., 404, 162, 10.1016/0006-8993(87)91367-9 · DOI
  74. Rossor, 1986, Non-cholinergic neurotransmitter abnormalities in Alzheimer's disease, Br. Med. Bull., 42, 70, 10.1093/oxfordjournals.bmb.a072101 · DOI
  75. Rusted, 1988, Dissociative effects of scopolamine on working memory in healthy young volunteers, Psychopharmacology, 96, 487, 10.1007/BF02180029 · DOI
  76. Safer, 1971, The central effects of scopolamine in man, Biol. Psychiatry, 3, 347
  77. Salmon, 1988, Lexical and semantic priming deficits in patients with Alzheimer's disease, J. Clin. Exp. Neuropsychol., 10, 477, 10.1080/01688638808408254 · DOI
  78. Schwartz, 1990, Loss of muscarinic M1 receptors with aging in the cerebral cortex of Fisher 344 rats, Pharmacol. Biochem. Behav., 35, 589, 10.1016/0091-3057(90)90295-S · DOI
  79. Sitaram, 1978, Human serial learning: enhancement with arecholine and choline and impairment with scopolamine, Science, 201, 27, 10.1126/science.351808 · DOI · Paper page
  80. Smith, 1978, Possible biochemical basis of memory disorder in Alzheimer disease, Ann. Neurol., 3, 471, 10.1002/ana.410030602 · DOI
  81. Strauss, 1985, Remembering words and how often they occurred in memory-impaired patients, Memory Cognition, 13, 507, 10.3758/BF03198321 · DOI
  82. Sunderland, 1987, Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls, Arch. Gen. Psychiatry, 44, 418, 10.1001/archpsyc.1987.01800170032006 · DOI
  83. Sunderland, 1988, Differential responsivity of mood, behavior and cognition to cholinergic agents in elderly neuropsychiatrie populations, Brain Res. Rev., 13, 371, 10.1016/0165-0173(88)90013-6 · DOI
  84. Sunderland, 1986, Pharmacologie modelling of Alzheimer's disease, Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 10, 599, 10.1016/0278-5846(86)90030-8 · DOI
  85. Sunderland, 1989, Low-dose oral lorazepam administration in Alzheimer subjects and age-matched controls, Psychopharmacology, 99, 129, 10.1007/BF00634466 · DOI
  86. Tariot, 1987, Cognitive effects of L-deprenyl in Alzheimer's disease, Psychopharmacology, 91, 489, 10.1007/BF00216016 · DOI
  87. Troster, 1989, Effects of scopolamine on anterograde and remote memory in humans, Psychobiology, 17, 12
  88. Troster, 1989, A comparison of the category fluency deficits associated with Alzheimer's and Huntington's disease, Brain Lang., 37, 500, 10.1016/0093-934X(89)90032-1 · DOI
  89. Warburton, 1981, Neurochemical bases of behavior, Br. Med. Bull., 37, 121, 10.1093/oxfordjournals.bmb.a071687 · DOI
  90. Weingartner, 1984, Cognitive impairments in Parkinson's disease: distinguishing between effort-demanding and automatic cognitive processes, Psychiatry Res., 11, 223, 10.1016/0165-1781(84)90071-4 · DOI
  91. Weingartner, 1983, Forms of memory failure, Science, 221, 380, 10.1126/science.6867715 · DOI
  92. Wesnes, 1990, The use of a scopolamine model to study the potential nontropic effects of aniracetam and piracetam in healthy volunteers, J. Psychopharmacol., 4, 219, 10.1177/026988119000400406 · DOI
  93. Wesnes, 1988, An investigation of the range of cognitive impairments induced by scopolamine 0–6 mg s.c, Human Psychopharmacol., 3, 27, 10.1002/hup.470030106 · DOI
  94. Wesnes, 1983, Effects of scopolamine on stimulus sensitivity and response bias in a visual vigilance task, Neuropsychobiology, 9, 154, 10.1159/000117954 · DOI
  95. Wesnes, 1984, Effects of scopolamine and nicotine on human rapid information processing performance, Psychopharmacology, 82, 147, 10.1007/BF00427761 · DOI
  96. White, 1977, Neocortical cholinergic neurons in elderly people, Lancet, 1, 668, 10.1016/S0140-6736(77)92114-6 · DOI
  97. Whitehouse, 1986, Cholinergic receptors in aging and Alzheimer's disease, Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 10, 665, 10.1016/0278-5846(86)90035-7 · DOI
  98. Whitehouse, 1986, Nicotinic acetylcholine binding sites in Alzheimer's disease, Brain Res., 371, 146, 10.1016/0006-8993(86)90819-X · DOI
  99. Wu, 1988, Decrease of brain acetylcholine release in freely-moving rats detected by microdialysis, Neurobiol. Aging, 9, 357, 10.1016/S0197-4580(88)80081-2 · DOI
  100. Zemishlany, 1991, Anticholinergic challenge and cognitive functions: a comparison between young and elderly normal subjects, Isr. J. Psychiatry Relat. Sci., 28, 32
  101. Zweig, 1988, The neuropathology of aminergic nuclei in Alzheimer's disease, Ann. Neurol., 24, 233, 10.1002/ana.410240210 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Molchan, S. E., Martinez, R. A., Hill, J. L., Weingartner, H. J., Thompson, K., Vitiello, B., & Sunderland, T.
Affiliations
  • National Institute of Mental Health (US)
  • National Institute on Alcohol Abuse and Alcoholism (US)
Corresponding author
Molchan, Susan E.
ORCID
Venue
Brain Research Reviews
Publisher
Elsevier BV
Published
1992-09
Volume
17
Issue
3
Pages
215-226
ISSN
0165-0173 (ISSN-L)
DOI
10.1016/0165-0173(92)90017-g
OpenAlex
W2039398668
Cited by
187
References
4
Citations by year
2026: 2 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 3 · 2021: 1 · 2020: 3 · 2019: 2 · 2018: 4 · 2017: 3 · 2016: 10 · 2015: 7 · 2014: 4 · 2013: 2 · 2012: 3
FWCI
5.78
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Brain Research Reviews (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
scopolamine, cholinergic system, normal aging, Alzheimer's disease, anticholinergic agents, learning and memory, attention, digit span, verbal fluency, episodic memory
MeSH terms
Acetylcholine, Adult, Aged, Aging, Alzheimer Disease, Arousal, Cognition, Double-Blind Method, Humans, Memory, Middle Aged, Models, Neurological, Psychological Tests, Scopolamine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review